葛兰素史克
✦ 量化合理价值 计算方式说明
- 基于该股自身过去5年平均市盈率乘以滚动每股收益,推算出的合理价值区间为30.21-72.04。
- 当前价格比按平均倍数计算的合理价值(51.12)低3.2%。
估值 各估值倍数与自身5年区间的对比
同业对比 Drug Manufacturers - General
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 葛兰素史克 (GSK) | 99.19B | 15.83 | 4.23 | 3.58% |
| Eli Lilly and Co (LLY) | 1.18T | 42.20 | 34.93 | 0.51% |
| Johnson & Johnson (JNJ) | 615.87B | 38.84 | 7.25 | 2.07% |
| AbbVie (ABBV) | 504.37B | 80.63 | -84.97 | 2.36% |
| Merck & Co (MRK) | 360.08B | 116.76 | 8.59 | 2.30% |
| Novartis AG (NVS) | 286.29B | 22.75 | 6.89 | 3.15% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算0.3%。
合理价值
GSK PLC earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 6% discount to our quantitative fair value estimate of $49.34 per share; however, some caution is warranted due to this estimate's medium uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The firm's profitability increases our fair value estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's earnings yield of 9.8% ranks in the top 20% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are undervalued.
Alternatively, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 24.7%, for example, lies in the bottom 30% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
经济护城河
The company earns a quantitative moat rating of wide, suggesting a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. This is supported by the company's strong financial health score, which indicates a low likelihood that the company will tumble into financial distress.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
葛兰素史克 讨论区 0 条评论